Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III Pivotal Clinical Trial to Evaluate LSD for the Treatment of Generalized Anxiety Disorder

Next Previous
X
Search
Trial Profile

A Phase III Pivotal Clinical Trial to Evaluate LSD for the Treatment of Generalized Anxiety Disorder

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 21 Jun 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lysergide (Primary)
  • Indications Generalised anxiety disorder
  • Focus Registrational; Therapeutic Use
  • Sponsors Mindmed

    • Most Recent Events

    • 20 Jun 2024 According to a Mindmed Media Release, following a constructive End-of-Phase 2 meeting with the FDA, company is pleased to have reached alignment on our Phase 3 development strategy for MM120 in GAD.
    • 20 Jun 2024 According to a Mindmed Media Release, company is on schedule to initiate our Phase 3 clinical program for MM120 oral dissolving tablet (ODT) in GAD in the second half of this year and look forward to sharing additional details on the design of the pivotal program in the coming months.
    • 14 Dec 2023 According to a Mindmed Media Release, results from Phase 2b Trial of MM-120 in Generalized Anxiety Disorder study will support the advancement of MM-120 into Phase 3 clinical development for GAD. The Company plans to hold an End-of-Phase 2 meeting with the FDA in the first half of 2024 and expects to initiate Phase 3 clinical trials in the second half of 2024.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top